Page 34 - JCTR-11-2

Journal of Clinical and

Translational Research

REVIEW ARTICLE
A comprehensive review of clinical advances in

the antifibrotic role of micro-RNA in pneumonia
and pulmonary fibrosis

Bhaskar Pal * , Said Afredi , Krishan Maity , and Kushal Roychoudhuri 1
1
3
1,2
1 Department of Pharmaceutical Technology, Charaktala College of Pharmacy, Debipur, West
Bengal, India
2 Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology,
Kolkata, West Bengal, India
3 Department of Pharmaceutical Technology, Bengal College of Pharmaceutical Science and
Research, Durgapur, West Bengal, India

Abstract

Background: Pneumonia is a common respiratory infection affecting millions of
people worldwide and often leads to serious complications such as pulmonary
fibrosis – a progressive disorder recognized by persistent scarring, alveolar thickening,
impaired gas exchange, and reduced lung capacity. The pathogenesis of pulmonary
fibrosis remains complex and poorly understood. A hallmark feature is the buildup
of extracellular matrix disrupting the normal architecture and function of the lung
*Corresponding author: parenchyma, ultimately causing irreversible lung damage. At present, there is no known
Bhaskar Pal
(palbhaskar96@gmail.com) remedy for pulmonary fibrosis, and the existing treatments are often limited in efficacy
and associated with adverse effects. This underscores the urgent need to identify novel
Citation: Pal B, Afredi S, Maity K, molecular targets and therapeutic approaches for this debilitating condition. Aim:

Roychoudhuri K. A comprehensive
review of clinical advances in the This review summarizes recent advances in understanding the pharmacotherapeutic
antifibrotic role of micro-RNA in potential of microRNAs (miRNAs) in reducing fibrosis associated with pneumonia and
pneumonia and pulmonary fibrosis. pulmonary fibrosis. It highlights the signaling mechanisms through which miRNAs
J Clin Transl Res. 2025;11(2):28-40.
doi: 10.36922/JCTR025080009 regulate gene expression, as well as their role in maintaining lung development and
homeostasis. The review also identifies the specific miRNAs with antifibrotic effects as
Received: February 17, 2025
demonstrated in experimental models and clinical settings. Finally, it discusses the key
Revised: March 5, 2025 challenges in developing miRNA-based therapies, including delivery strategies and off-
Accepted: April 3, 2025 target effects. Methods: The study entailed a thorough literature review on antifibrotic
effect of mi-RNA in pneumonia and lung fibrosis, conducted through the electronic
Published online: April 24, 2025
searches on Google, Google Scholar, and PubMed databases. Results: In his study we
Copyright: © 2025 Author(s). provide a recent finding on antifibrotic activity of miRNA in pulmonary complications.
This is an open-access article
distributed under the terms of the Moreover, the evidences from animal and clinical researches are also discussed. This
Creative Commons AttributionNon- may further help scholars, practitioners, and legislators who are interested to do the
Commercial 4.0 International (CC research on mi-RNA therapies in clinical practice. Conclusion: In conclusion, miRNA-
BY-NC 4.0), which permits all
non-commercial use, distribution, based diagnostics and therapies represent a promising frontier for the management
and reproduction in any medium, of pneumonia and pulmonary fibrosis. Further research is warranted to deepen our
provided the original work is understanding of miRNA mechanisms in the therapeutic context. Relevance for
properly cited. patients: Advances in therapies for pneumonia and pulmonary fibrosis can enhance
Publisher’s Note: AccScience treatment efficacy, aiding in the mitigation and treatment of the disease.
Publishing remains neutral with
regard to jurisdictional claims in
published maps and institutional Keywords: Pneumonia; Pulmonary fibrosis; Myofibroblasts; Pharmacotherapeutics; MicroRNA
affiliations.

Volume 11 Issue 2 (2025) 28 doi: 10.36922/JCTR025080009